CDK9-IN-7;7H-Pyrrolo[2,3-d]pyrimidine-6-carboxamide, 7-cyclopentyl-2-[[4-[(8-isothiocyanato-1-oxooctyl)amino]phenyl]amino]-N,N-dimethyl-;CDK-9-IN-7,CDK9IN7,CDK9 IN 7;CDK9-IN-7, 10 mM in DMSO;7-cyclopentyl-2-((4-(8-isothiocyanatooctanamido)phenyl)amino)-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide
CDK9-IN-7 is a potent, selective, and orally active CDK9/cyclin T inhibitor (IC50 = 11 nM) with anticancer activity and minimal toxicity; it induces apoptosis in non-small cell lung cancer (NSCLC) cells, arrests the cell cycle at the G2 phase, and suppresses NSCLC stem cell-like properties; it exhibits exceptional potency against NSCLC cell lines, particularly A549 and H1299 (IC50 < 0.5 µM), and shows effective inhibition in the drug-resistant NSCLC cell line H1975 (IC50 = 0.837 µM).